RxDoctor Payments Data

Sukanya Venkatachalam, MD

Psychiatry · Pleasanton, CANPI 1083878078

Payments from drug & device makers

$1,911in general payments, 2019–2025

Across 73 payments — averaging $26.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$429
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$241
  • Axsome Therapeutics, Inc.$233
  • Neurocrine Biosciences, Inc.$174
  • Johnson & Johnson$122
  • Teva Pharmaceuticals USA, Inc.$117
  • plus $593 from 10 others

What the payments were for

  • Food & beverage$1,911100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,911 in reported general payments places this provider in the 80th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$44,421
Medicare patients
62
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide59$40,905
VraylarCariprazine Hcl13$29,878
Modafinil21$25,292
Risperdal ConstaRisperidone Microspheres24$20,970
Duloxetine Hcl64$2,834
Aripiprazole33$2,668
Venlafaxine Hcl ErVenlafaxine Hcl43$2,228
Bupropion XlBupropion Hcl39$1,649
Olanzapine37$1,448
Alprazolam65$1,091
Trazodone Hcl59$952
Mirtazapine30$889
Doxepin Hcl13$854
Gabapentin40$834
Quetiapine Fumarate51$727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$84$40,90559 claims
AbbVieVraylar$16$29,87813 claims
Johnson & JohnsonRisperdal Consta$122$20,97024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Pleasanton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →